Danske Bank’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Danske Bank’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-100	Closed	-$13.2K	–	1599
2025 Q1	$13.2K	Hold	100	–	–	﹤0.01%	1031
2024 Q4	$8.35K	Sell	100 -1,300	-93%	-$107K	﹤0.01%	1132
2024 Q3	$102K	Buy	+1,400	New	+$105K	﹤0.01%	1009
2024 Q2	–	Sell	-37,700	Closed	-$2.61M	–	1269
2024 Q1	$2.61M	Buy	+37,700	New	+$2.59M	0.01%	647

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Danske Bank's ITCI Position: Q2 2025 in Review

Danske Bank sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 100 shares — an estimated $13.2K sold.

Danske Bank first reported a position in ITCI in Q1 2024 and held it in 4 quarters. The position peaked at $2.61M in Q1 2024. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Danske Bank reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Danske Bank sold 100 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $13.2K.
Danske Bank first reported a position in Intra-Cellular Therapies Inc. in Q1 2024 and held it in 4 quarters.
Danske Bank's Intra-Cellular Therapies Inc. position peaked at $2.61M in Q1 2024.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Danske Bank's 13F filing for Q2 2025, filed 18 Dec 2025.